Clinical Trials Browser

Active not recruiting × Albumin-Bound Paclitaxel × Clear all

NCT07280377 2026-05-19

GOBLET

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04310007 2026-05-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT04104672 2026-05-07

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02270814 2026-05-05

CACTUX

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04233866 2026-05-05

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT02495896 2026-04-29

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05771480 2026-04-21

TOURMALINE

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05632328 2026-04-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05497778 2026-04-16

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06132958 2026-04-03

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT01525966 2026-03-30

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

Non-Small Cell Lung Cancer Metastatic

NCT00616967 2026-03-05

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Phase 2 Active not recruiting

68 enrolled 17 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT07374003 2026-01-28

Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

42 enrolled 13 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04831320 2025-12-30

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT02481635 2025-12-08

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT02207465 2025-11-19

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

NCT06139419 2025-11-17

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

Invasive Breast Cancer

NCT05669482 2025-09-02

RAMP205

Phase 1/2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT01463072 2025-07-28

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

40 enrolled 17 charts

Breast Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Phase 2 Active not recruiting

29 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06009861 2025-06-06

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

Phase 2 Active not recruiting

63 enrolled 11 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02340117 2025-05-30

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms